

CURRICULUM VITAE

Name: Zachary S. Zumsteg, M.D.

Business Data Address: CSMC Department of Radiation Oncology
8700 Beverly Blvd., AC 1022
Los Angeles, CA 90048
Telephone: (310) 423-8077

Education and Training:

1999-2003 B.M. in Music Engineering, University of Miami, Coral Gables, FL
2003-2005 M.S. in Electrical Engineering, Stanford University, Stanford, CA
2005-2010 M.D., David Geffen School of Medicine at UCLA, Los Angeles CA
2008-2009 Howard Hughes Medical Institute Research Training Fellowship
Department of Radiation Oncology, UCLA
2010-2011 Internship, Internal Medicine, UCLA-Olive View Medical Center,
Sylmar, CA
2011-2015 Resident, Department of Radiation Oncology, Memorial Sloan
Kettering Cancer Center, New York, NY
2014-2015 Chief Resident, Department of Radiation Oncology, Memorial
Sloan Kettering Cancer Center, New York, NY

Licensure: California, Physician Medical License, Exp. 1/2019
New York, Physician Medical License, Exp. 6/2017

Board Certification: Radiation Oncology, Physics & Radiobiology, 2014
Radiation Oncology, Written Clinical, 2015
Radiation Oncology, Oral Clinical Boards, 2016

Professional Experience:

Current Appointment

Assistant Professor, Cedars-Sinai Medical Center
Staff Physician I, Cedars-Sinai Medical Center

Professional Activities:

National Committee Involvement

NRG GU Core Committee- Member
NRG New Investigator Committee- Member

Institutional Committee Involvement

Cedars-Sinai SOCCI Translational Oncology Program- Cohort Study Group Leader
Cedars-Sinai Tumor Registry Committee- Member
Cedars-Sinai Head and Neck Cancer Disease Research Group- Member

Journal Reviewer

Journal of Clinical Oncology- Ad Hoc Reviewer
International Journal of Radiation Oncology Biology Physics- Ad Hoc Reviewer
American Journal of Clinical Oncology- Ad Hoc Reviewer
Prostate Cancer and Prostatic Disease- Ad Hoc Reviewer
Brachytherapy- Ad Hoc Reviewer
Journal of Urology- Ad Hoc Reviewer
Oncotarget- Ad Hoc Reviewer
Radiation Oncology- Ad Hoc Reviewer
Clinical Skin Cancer- Ad Hoc Reviewer

Professional Societies

American Society for Radiation Oncology (ASTRO)
New York Roentgen Society

Honors and Special Awards:

2017	SuperDoctors Southern California Rising Stars 2017
2014	ASTRO Annual Meeting Scientific Abstract Travel Award: Biology
2013	Best of ASTRO Abstract Selection
2010	Alpha Omega Alpha Medical Honor Society
2009	Radiation Research Society Scholars-In-Training Award
2008	Howard Hughes Medical Institute Research Training Fellowship
1999-2003	Joseph Hirschberg Physics Award
1999-2003	Constance Weldon Scholarship
1999	National Merit Scholarship

Academic Mentoring

2015-2018	Emi Yoshida (Cedars-Sinai Radiation Oncology Resident)
2015-2018	John David (Cedars-Sinai Radiation Oncology Resident)
2016	Matthew Schmidt (Creighton University Medical Student)
2016-2017	Katri Aro (Visiting Research Fellow)
2017-present	Eric Anderson (Cedars-Sinai Radiation Oncology Resident)
2017-present	Mark Sittig (Cedars-Sinai Radiation Oncology Resident)
2018-present	Diana Lu (Cedars-Sinai Radiation Oncology Resident)

Clinical Trials- Principal Investigator

1. Site Principal Investigator, RTOG 0920: "A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920)"
2. Site Principal Investigator, NRG HN003: "A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)"

Bibliography/Publications

Peer-Reviewed Original Research

1. **Zumsteg ZS**, Kemere C, O'Driscoll S, Santhanam G, Ahmed RE, Shenoy KV, Meng TH. Power Feasibility of Implantable Digital Spike-Sorting Circuits for Neural Prosthetic Systems. *IEEE Trans Neural Syst Rehabil Eng.* 2005 Sep;13(3):272-9.
2. **Zumsteg Z**, DeMarco J, Lee SP, Steinberg ML, Lin CS, McBride W, Lin K, Wang PC, Kupelian P, Lee P. Image Guidance During Head-and-Neck Cancer Radiation Therapy: Analysis of Alignment Trends with In-Room Cone-Beam Computed Tomography Scans. *Int J Radiat Oncol Biol Phys.* 2012; 83:712-9.
3. **Zumsteg ZS**, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. *Int J Radiat Oncol Biol Phys.* 2013 Mar 15;85(4):1012-7.
4. Spratt DE, **Zumsteg Z**, Ghadjar P, Pangasa M, Pei X, Fine SW, Yamada Y, Kollmeier M, Zelefsky MJ. Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis. *Int J Radiat Oncol Biol Phys.* 2013 Apr 1;85(5):1254-61.
5. Spratt DE, Zhang C, **Zumsteg ZS**, Pei X, Zhang Z, Zelefsky MJ. Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. *Eur Urol.* 2013;63:709-16
6. **Zumsteg ZS**, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. *Eur Urol.* 2013 Dec;64(6):895-902.
7. Perez CA, **Zumsteg ZS**, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick B, Powell SN, Ho AY. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. *Breast Cancer Res Treat.* 2013 Jun;139(2):497-506.
8. **Zumsteg ZS**, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, Traina T, McCormick B, Powell S, Ho AY. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. *Ann Surg Oncol.* 2013 Oct;20(11):3469-76.
9. Spratt DE, Folkert M, **Zumsteg ZS**, Chan TA, Beal K, Gutin PH, Pentsova E, Yamada Y. Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. *J Neurooncol.* 2014 Jan;116(2):357-63.
10. Spratt DE, **Zumsteg ZS**, Ghadjar P, Kollmeier MA, Pei X, Cohen G, Polkinghorn W, Yamada Y, Zelefsky MJ. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. *BJU Int.* 2014 Sep;114(3):360-7.
11. Spratt DE, **Zumsteg ZS**, Romesser PB, Pei X, Yamada J, Wu K, Zhang Z, Zelefsky MJ. Predictors of Castration-Resistant Prostate Cancer After Dose-Escalated External Beam Radiotherapy. *Prostate.* 2015 Feb;75(2):175-82.

12. **Zumsteg ZS**, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ. The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing External Beam Radiotherapy. *Eur Urol*. 2015 Jun;67(6):1009-16.
13. **Zumsteg ZS**, Riaz N, Jaffrey S, Hu M, Gelblum D, Zhou Y, Mychalczak B, Zelefsky MJ, Wolden S, Rao S, Lee NY. Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. *Oral Oncol*. 2015 Jul;51(7):716-23.
14. **Zumsteg ZS**, Spratt DE, Romesser PB, Pei X, Zhang Z, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ. Anatomic Patterns of Recurrence Following Biochemical Relapse in the Dose-Escalation Era for Prostate Patients Undergoing External Beam Radiotherapy. *J Urol*. 2015 Dec;194(6):1624-30.
15. Spratt DE, Beadle BM, **Zumsteg ZS**, Rivera A, Skinner HD, Osborne JR, Garden AS, Lee NY. The influence of diabetes mellitus and metformin on distant metastases in oropharyngeal cancer: A multicenter study. *Int J Radiat Oncol Biol Phys*. 2016 Mar 1;94(3):523-31.
16. **Zumsteg ZS**, Morse N, Kringsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J. Taselisib (GDC-0032), a Potent β -sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Cell Carcinomas Containing Activating *PIK3CA* Alterations. *Clin Cancer Res*. 2016 Apr 15;22(8):2009-19.
17. Spratt DE, Osborne JR, **Zumsteg ZS**, Leeman J, Rivera A, Morris M, Zelefsky MJ. Radium-223 Outcomes after Multiple Lines of Castration-Resistant Prostate Cancer Therapy: Implications of Pre-treatment Spinal Epidural Disease on Radium-223 Outcomes. *Prostate Cancer Prostatic Dis*. *Prostate Cancer Prostatic Dis*. 2016 Sep;19(3):271-6.
18. Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Soni PD, Hamstra D, Lee JY, Dess RT, Zhao G, Talmich E, Cole AI, **Zumsteg ZS**, Sandler H, Palapattu G, Mehra R, Morgan TM, Feng FY. Independent Validation of the Prognostic Capacity of the New Prostate Cancer Grade Grouping System for Radiation Treated Patients with Long-term Follow-up. *Prostate Cancer Prostatic Dis*. 2016 Sep;19(3):292-7.
19. Sacks WL, Bose S, **Zumsteg ZS**, Wong R, Shiao SL, Braunstein GD, Ho AS. Impact of Afirma GEC on Cytopathology Diagnosis and Rate of Thyroidectomy. *Cancer Cytopathol*. 2016 Oct;124(10):722-728.
20. **Zumsteg ZS**, Cooks-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, Jeon C, Goodman MT, Ho AS. The Increasing Incidence of Oropharyngeal Cancers Among Elderly Patients in the United States. *JAMA Oncol*. 2016 Dec 1;2(12):1617-1623.
21. Ho AS, **Zumsteg ZS**, Meyer A, Riaz N, Rahmati R, Kraus DH, McCarthy C, Wong RJ, Shah JP, Lee NY. Impact of Flap Reconstruction on Radiotoxicity After Salvage Surgery and Reirradiation for Recurrent Head and Neck Cancer. *Ann Surg Oncol*. 2016 Dec;23(Suppl 5):850-857.
22. Spratt DE, Vargas HA, **Zumsteg ZS**, Golia Pernicka JS, Osborne JR, Pei X, Zelefsky MJ. Patterns of Lymph Node Failure after Dose-escalated

Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. *Eur Urol.* 2017 Jan;71(1):37-43.

23. **Zumsteg ZS**, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Number of Unfavorable Intermediate Risk Factors Predicts for Pathologic Upstaging and Prostate Cancer Specific Mortality Following Radical Prostatectomy: A SEARCH Database Analysis. *Prostate.* 2017 Feb;77(2):154-163.
24. Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, **Zumsteg ZS**, Mehra R, Feng FY, Morgan TM, Desai N, Spratt DE. 'Very Early' Salvage Radiotherapy Improves Distant Metastasis-Free Survival. *J Urol.* 2017 Mar;197(3 Pt 1):662-668.
25. **Zumsteg ZS**, Lok B, Ho AS, Drille E, Zhang Z, Riaz N, Shiao SL, Ma J, McBride S, Tsai J, Baxi S, Sherman E, Lee NY. The Toxicity and Efficacy of Concomitant Chemoradiotherapy in Patients Aged 70 and Older with Oropharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era. *Cancer.* 2017 Apr 15;123(8):1345-1353.
26. **Zumsteg ZS**, Kim S, David J, Yoshida E, Tighiouart M, Shiao SL, Scher K, Mita A, Sherman E, Lee NY, Ho AS. The Impact of Chemoradiation on Survival for Patients with T1-2N1 Head and Neck Cancer. *Cancer.* 2017 May 1;123(9):1555-1565.
27. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, **Zumsteg ZS**, Feng FY, Hamstra DA, Collins SP, Spratt DE. Predictors of Multi-Domain Decline in Health Related Quality of Life after Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer. *Cancer.* 2017 May 1;123(9):1635-1642.
28. Jackson WC, Desai N, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, **Zumsteg ZS**, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE. Anatomic Patterns of Recurrence Following Biochemical Relapse after Post-Prostatectomy Salvage Radiation Therapy: A Multi-Institutional Study. *BJU Int.* 2017 Sep;120(3):351-357.
29. David JM, Ho AS, Luu M, Yoshida EJ, Kim S, Mita AC, Scher KS, Shiao SL, Tighiouart M, **Zumsteg ZS**. Treatment at High-Volume Facilities and Academic Centers Is Independently Associated With Improved Survival in Patients With Locally Advanced Head and Neck Cancer. *Cancer.* 2017 Oct 15;123(20):3933-3942.
30. Schmidt MQ, David J, Yoshida EJ, Scher K, Mita A, Shiao SL, Ho AS, **Zumsteg ZS**. Predictors of survival in head and neck mucosal melanoma. *Oral Oncol.* 2017 Oct;73:36-42.
31. Leeman J, Li J, Pei X, Venigalla P, **Zumsteg ZS**, Katsoulakis E, Lupovitch E, McBride SM, Tsai CJ, Boyle J, Roman B, Morris L, Dunn L, Sherman EJ, Lee NY, Riaz N. The Natural History and Patterns of Failure After Recurrence in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Treated with Modern Definitive Therapy. *JAMA Oncol.* 2017 Nov 1;3(11):1487-1494.
32. **Zumsteg ZS**, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z. Unification of favorable intermediate, unfavorable

- intermediate, and very high risk-stratification criteria for prostate cancer. *BJU Int.* 2017 Nov;120(5B):E87-E95.
33. Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Van Eyk JE, **Zumsteg ZS**. Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer. *J Clin Oncol.* 2017 Nov 1;35(31):3601-3609.
 34. **Zumsteg ZS**, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita A, Scher K, Sherman EJ, Lee NY, Ho AS. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. *Cancer.* 2017 Dec 1;123(23):4583-4593.
 35. **Zumsteg ZS**, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. *Prostate.* 2017 Dec;77(16):1592-1600.
 36. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, **Zumsteg ZS**, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE. Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer. *BJU Int.* 2018 Jan;121(1):61-68.
 37. Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Lee NY, Ho AS, **Zumsteg ZS**. Facility Volume and Survival in Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2018 Feb 1;100(2):408-417.
 38. Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, **Zumsteg ZS**, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB. Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study. *BJU Int.* 2017 Jun 5. doi: 10.1111/bju.13926.
 39. Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Ali N, Patio C, Mallen-St. Clair J, Van Eyk JE, **Zumsteg ZS**. Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer. *JAMA Oncol.* 2017 Nov 30. doi: 10.1001/jamaoncol.2017.3852. [Epub ahead of print]
 40. Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Ho AS, **Zumsteg ZS**. Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification. *Head Neck.* 2018 Feb 8. doi: 10.1002/hed.25100. [Epub ahead of print]

Review Articles

1. **Zumsteg ZS**, Zelefsky MJ. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? *Lancet Oncol.* 2012; 13:e259-69.
2. Castel P, Toska E, **Zumsteg ZS**, Carmona J, Elkabets M, Bosch A, Scaltriti M. Rationale-based therapeutic combinations with PI3K inhibitors in cancer. *Mol Cell Oncol.* 2014;1(3):e963447.
3. Samim F, Epstein JB, **Zumsteg ZS**, Ho AS, Barasch A. Oral and Dental Health in Head and Neck Cancer Survivors. *Cancers of the Head and Neck.* 2016

4. Spratt DE, **Zumsteg ZS (co-first author)**, Feng FY, Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer. *Nat Rev Clin Oncol*. 2016 Oct;13(10):597-610.
5. **Zumsteg ZS**, Daskivich TJ, Sandler HS. Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy. *J Clin Oncol*. 2016 Aug 29. pii: JCO692509. [Epub ahead of print]
6. Maggiore R, **Zumsteg ZS (co-first author)**, BrintzenhofeSzoc K, Trevino KM, Gajra A, Korc-Grodzicki B, Epstein JB, Bond SM, Parker I, Kish JA, Murphy BA, Vanderwalde NA; CARG-HNC Study Group.. The Older Adult with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment. *Int J Radiat Oncol Biol Phys*. 2017 Jul 15;98(4):868-883.
7. Spratt DE, Dess RT, **Zumsteg ZS**, Lin DW, Tran PT, Morgan TM, Antonarakis, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. A Systemic Review and Framework for the Use of Hormonal Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. *Eur Urol*. 2018 Feb;73(2):156-165.
8. Sroussi H, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RV, Migliorati CA, Heavilin N, **Zumsteg ZS**. Common Oral Complications of Head and Neck Cancer Radiation Therapy: Mucositis, Infections, Saliva Change, Fibrosis, Sensory Dysfunctions, Dental Caries, Periodontal Disease, and Osteoradionecrosis. *Cancer Med*. 2017 Dec;6(12):2918-2931.

Editorials, Letters to the Editor, Case Reports, and Other Published Articles

1. **Zumsteg ZS**, Ng AK. MALT Lymphoma of the Breast: Bilateral Metachronous Presentation. *Leukemia and Lymphoma*. 2010;51:168-70
2. **Zumsteg ZS**, Zelefsky MJ. Improved Survival with Surgery in Prostate Cancer Patients Without Medical Comorbidity: A Self-fulfilling Prophecy? *Eur Urol*. 2013 Sep;64(3):381-3.
3. **Zumsteg ZS**, Riaz N, Lee NY. Adjuvant Radiotherapy Following Elective Versus Therapeutic Neck Dissection. *New England Journal of Medicine*. 2015;373(25):2475-2477.
4. Gutiontov SI, **Zumsteg ZS**, Lok BH, Berry S, Tsai CH, McBride SM, Riaz N, Cahlon O, Lee NY. Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck. *International Journal of Particle Therapy*: Winter 2017, Vol. 3, No. 3, pp. 421-428.
5. Wong FK, **Zumsteg ZS**, Langevin CJ, Ali N, Maclary S, Balzer BL, Ho AS. Mucinous Carcinoma with Neuroendocrine Differentiation of Salivary Gland Origin. *Head Neck Pathol*. 2017 Jun;11(2):249-255.

Book Chapters

1. **Zumsteg Z**, Riaz N, Lee N. Larynx Cancer. *Target Delineation and Field Set-up: A Practical Guide For Conformal and Intensity-Modulated Radiation Therapy*. 2015
2. **Zumsteg Z**, Sandler H. IMRT for Teal. *The Key to Prostate Cancer*. 2017

3. Sampath S, Vora N, **Zumsteg Z**. Radiation Therapy for the Head and Neck Patient: Advances, Challenges, and Perspectives. *Multidisciplinary Care of the Head and Neck Cancer Patient*. 2018

Selected Published Abstracts

1. **Zumsteg ZS**, Ahmed RE, Santhanam G, Shenoy KV, Meng TH, "Power Feasibility of Implantable Digital Spike-Sorting Circuits for Neural Prosthetic Systems," *Proceeding of the 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society*, 2004. Volume 2, September 2004 pp. 4237 - 4240
2. **Zumsteg ZS**, McBride WH, Cacalano NA, Iwamoto KS, Damoiseaux R, Vlashi E, Kim K . High throughput screening of small molecule libraries to identify novel 26S proteasome inhibitors. Poster presentation at the American Association of Cancer Research Annual Meeting, April 2009.
3. **Zumsteg Z**, DeMarco J, Lee SP, Steinberg M, Singhvi M, Lin T, Julliard G, McBride W, Lin K, Lee PP. Using Megavoltage Cone Beam CT (MV CBCT) in Image-guided Radiation Therapy for Head and Neck Cancers. Poster Presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, November 2009.
4. **Zumsteg ZS**, Cacalano NA, Belanto JJ, Yeh BK, Pham V, Jamieson CA, Iwamoto K, McBride WH, Kim K. Thiostrepton, a novel proteasome inhibitor, downregulates FoxM1 expression and is a radiosensitizing agent in glioblastoma multiforme. Poster Presentation at the Radiation Research Society Annual Meeting, October 2009. Awarded RRS Scholars-in-training Travel Award.
5. **Zumsteg ZS**, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, Brogi E, McCormick B, Powel SN, Ho AY. Breast-Conserving Therapy Achieves Equivalent Locoregional Outcomes Compared to Mastectomy in Women with T1-2N0 Triple Negative Breast Cancer. Poster Discussion at the American Society for Therapeutic Radiology and Oncology Annual Meeting, October 2012.
6. **Zumsteg ZS**, Spratt DE, Pei X, Yamada Y, Kuk D, Zhang Z, Zelefsky MJ. Short-Term Androgen Deprivation Decreased Distant Metastasis and Prostate Cancer Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External-Beam Radiotherapy. Oral Presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, October 2012.
7. **Zumsteg ZS**, Spratt DE, Romesser P, Pei X, Polkinghorn W, Kollmeier M, Yamada Y, Zelefsky MJ. The Natural History and Patterns of Failure Following Biochemical Relapse in Prostate Cancer (PC) Patients Treated with Dose Escalated External Beam Radiotherapy (EBRT). Oral Presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, September 2013. Selected for presentation at the Best of ASTRO 2013 Meeting.
8. **Zumsteg ZS**, Morse N, Higginson D, Gupta G, Morris L, Ganly I, Grandis J, Lee NY, Powell SN, Scaltriti M, Baselga J. GDC-0032, A Novel p110 α Inhibitor, Specifically Radiosensitizes Head and Neck Squamous Cell Carcinomas

Harboring Activating *PIK3CA* Alterations. Oral Presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, September 2014. Selected for an ASTRO Annual Meeting Scientific Abstract Travel Award: Biology.

9. **Zumsteg ZS**, Kollmeier M, Gardner G, Abu-Rustum N, Alektiar K. Redefining High Intermediate Risk Disease In Patients With Stage I-II Myometrial Invasive Endometrioid Adenocarcinoma. Poster discussion at the American Society for Therapeutic Radiology and Oncology Annual Meeting, October 2015.
10. **Zumsteg ZS**, Beadle BM, Spratt DE, Rivera A, Skinner HD, Osborne JR, Garden AS, Lee NY. The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. ASTRO 2016 Multidisciplinary Head and Neck Cancer Symposium, February 2016.
11. **Zumsteg ZS**, Lok B, Ho AS, Riaz N, Shiao SL, McBride S, Tsai J, Baxi S, Sherman E, Lee NY. The Toxicity and Efficacy of Concomitant Chemoradiotherapy in Elderly Patients with Oropharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era. Poster presentation, American Society of Clinical Oncology Annual Meeting, June 2016.
12. **Zumsteg ZS**, Cooks-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, Jeon C, Goodman MT, Ho AS. The Increasing Incidence of Oropharyngeal Cancers Among Elderly Patients in the United States. American Society for Therapeutic Radiology and Oncology Annual Meeting, October 2016.
13. **Zumsteg ZS**, Spratt DE, Pei X, Zhang Z, Woo K, Kollmeier M, McBride S, Sandler H, Zelefsky MJ. Redefining Unfavorable Risk Prostate Cancer: A Novel Risk Stratification Paradigm for Enhanced Outcome Prediction via Harmonization and Unification of Risk Stratification Criteria. Poster Presentation, American Society for Therapeutic Radiology and Oncology Annual Meeting, October 2016.
14. **Zumsteg ZS**, Kim S, David J, Yoshida E, Tighiouart M, Shiao SL, Scher K, Mita A, Sherman E, Lee NY, Ho AS. The Impact of Chemoradiation on Survival for Patients with T1-2N1 Head and Neck Cancer. Poster Presentation, American Head and Neck Society Meeting, April 2017.